Literature DB >> 25712358

Kidney injury associated with telavancin dosing regimen in an animal model.

Vincent H Tam1, Kimberly R Ledesma2, Dana R Bowers2, Jian Zhou2, Luan D Truong3.   

Abstract

The elevation of serum creatinine levels is a concern with telavancin therapy. We examined the onset of kidney injury associated with telavancin in an animal model. Urine samples were collected at baseline and daily to determine the concentrations of kidney injury molecule 1 (KIM-1), a marker for early kidney injury. When a clinically relevant exposure of telavancin was given daily to rats, some differences in kidney injury were attributed to the dosing regimen. Further investigations of alternative telavancin dosing regimens are warranted.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25712358      PMCID： PMC4394766          DOI： 10.1128/AAC.05002-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design.

Authors:  Kamilia Abdelraouf; Kirk H Braggs; Taijun Yin; Luan D Truong; Ming Hu; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

2.  Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies.

Authors:  Vishal S Vaidya; Josef S Ozer; Frank Dieterle; Fitz B Collings; Victoria Ramirez; Sean Troth; Nagaraja Muniappa; Douglas Thudium; David Gerhold; Daniel J Holder; Norma A Bobadilla; Estelle Marrer; Elias Perentes; André Cordier; Jacky Vonderscher; Gérard Maurer; Peter L Goering; Frank D Sistare; Joseph V Bonventre
Journal:  Nat Biotechnol       Date:  2010-05       Impact factor: 54.908

3.  Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.

Authors:  Sharath S Hegde; Noe Reyes; Tania Wiens; Nicole Vanasse; Robert Skinner; Julia McCullough; Koné Kaniga; John Pace; Roger Thomas; Jeng-Pyng Shaw; Glen Obedencio; J Kevin Judice
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

4.  Simulated human serum profiles of one daily dose of ceftriaxone plus netilmicin in treatment of experimental streptococcal endocarditis.

Authors:  M Blatter; U Fluckiger; J Entenza; M P Glauser; P Francioli
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

5.  Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.

Authors:  Mark H Gotfried; Jeng-Pyng Shaw; Bret M Benton; Kevin M Krause; Michael R Goldberg; Michael M Kitt; Steven L Barriere
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

6.  Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.

Authors:  Martin E Stryjewski; Donald R Graham; Samuel E Wilson; William O'Riordan; David Young; Arnold Lentnek; Douglas P Ross; Vance G Fowler; Alan Hopkins; H David Friedland; Steven L Barriere; Michael M Kitt; G Ralph Corey
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

Review 7.  Telavancin: a novel lipoglycopeptide.

Authors:  Louis D Saravolatz; Gary E Stein; Leonard B Johnson
Journal:  Clin Infect Dis       Date:  2009-12-15       Impact factor: 9.079

8.  Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy.

Authors:  Paul R Ingram; David C Lye; Dale A Fisher; Wei-Ping Goh; Vincent H Tam
Journal:  Int J Antimicrob Agents       Date:  2009-09-09       Impact factor: 5.283

9.  Evaluation of novel acute urinary rat kidney toxicity biomarker for subacute toxicity studies in preclinical trials.

Authors:  Tobias Christian Fuchs; Katharina Frick; Barbara Emde; Stephanie Czasch; Friedrich von Landenberg; Philip Hewitt
Journal:  Toxicol Pathol       Date:  2012-05-11       Impact factor: 1.902

10.  Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.

Authors:  Ethan Rubinstein; Tahaniyat Lalani; G Ralph Corey; Zeina A Kanafani; Esteban C Nannini; Marcelo G Rocha; Galia Rahav; Michael S Niederman; Marin H Kollef; Andrew F Shorr; Patrick C Lee; Arnold L Lentnek; Carlos M Luna; Jean-Yves Fagon; Antoni Torres; Michael M Kitt; Fredric C Genter; Steven L Barriere; H David Friedland; Martin E Stryjewski
Journal:  Clin Infect Dis       Date:  2011-01-01       Impact factor: 9.079
View more
  5 in total

1.  Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis.

Authors:  Truc T Tran; Vincent H Tam; Barbara E Murray; Cesar A Arias; Kavindra V Singh
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

Review 2.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

3.  Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment.

Authors:  Wanhong Wu; Meng Ke; Lingling Ye; Cuihong Lin
Journal:  Eur J Clin Pharmacol       Date:  2021-01-15       Impact factor: 2.953

Review 4.  Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.

Authors:  Valentin Al Jalali; Markus Zeitlinger
Journal:  Clin Pharmacokinet       Date:  2018-07       Impact factor: 6.447

5.  Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials.

Authors:  Boris Nogid; Melinda K Lacy; Micah Jacobs; Jon Bruss; Jamie Dwyer
Journal:  Pharmacotherapy       Date:  2018-08-29       Impact factor: 4.705
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.